Macrocyclic pyridazinone derivatives

1. A method of treating a disease related to IRAK overexpression, the method comprising:

administering an effective amount of a compound to a subject in need thereof,

wherein the compound is a compound of formula (I)

wherein

R1, R3 denote each, independently of one another H, (CH 2 ) p CON(R5) 2 , OA, Hal, COOH, COOA, (CH 2 ) p NHCOA, (CH 2 ) p Het1, (CH 2 ) p NR2R5, or OH;

R2 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms, wherein one or two H atoms of the alkyl group are optionally replaced by OR6, NR5R6, NHCOR5, CONR5R6;

R4 denotes H or A;

R5 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms;

R6 denotes H or linear or branched alkyl with 1, 2 or 3 C atoms;

Z is absent or denotes Ar-diyl or Het-diyl;

L denotes (CH 2 ) n wherein one or two CH 2 groups are optionally replaced by O and/or a CH═CH-group, and/or wherein one or two H atoms are optionally replaced by OR2, NR2R5 or Het1;

Ar-diyl denotes 1,2-, 1,3- or 1,4-phenylen optionally substituted with from 1 to 5 groups independently selected from the group consisting of Hal, CN, —CF 3 , —OCF 3 , OH, O-A, SO 2 -A, COOH, COOA, —CO-A, O-phenyl, SO 2 -phenyl, SO 2 —CF 3 , Het2 and A;

Het-diyl denotes an unsaturated, saturated or aromatic 5- or 6-membered heterocycle comprising 1 to 2 N, O and/or S atoms, which are optionally unsubstituted or mono-, di- or trisubstituted by Hal, CN, —CF 3 , —OCF 3 , O-A, SO 2 -A, COOH, COOA, —CO-A, O-phenyl, SO 2 -phenyl, SO 2 —CF 3 , Het2 and/or A;

A denotes an unbranched or branched alkyl comprising 1 to 10 C atoms, in which 1 to 5H atoms are optionally replaced by F and/or in which one or two non-adjacent CH 2 groups are optionally replaced by O;

Het1 denotes morpholinyl, piperidinyl or pyrrolidinyl;

Het2 denotes morpholinyl, piperidinyl or pyrrolidinyl;

Hal denotes F, Cl, Br, I;

n denotes 1, 2, 3, 4, 5 or 6;

p denotes 0, 1 or 2;

or wherein the compound is a pharmaceutically acceptable salt of a compound of formula (I);

wherein said disease related to IRAK overexpression is selected from the group consisting of systemic lupus erythematosus, lupus nephritis and rheumatoid arthritis.

2. The method of claim 1 , wherein the compound is administered as a pharmaceutical composition, which additionally comprises at least one further medicament effective for treatment of an inflammatory disease and/or an immune disorder.

3. The method of claim 2 , wherein the pharmaceutical composition additionally comprises at least one further immunomodulating agent.

4. The method of claim 1 , wherein, in the compound, R4 is H or methyl.

5. The method of claim 1 , wherein, in the compound, Het-diyl denotes pyridine-diyl, pyrimidine-diyl, pyridazin-diyl, pyrazol-diyl, imidazol-diyl, piperidin-diyl or pyrrolidin-diyl, each of which is unsubstituted or disubstituted by A.

6. The method of claim 1 , wherein, in the compound, Z is 1,3-phenylen, which is unsubstituted or monosubstituted by A, Hal, OH, or OA.

7. The method of claim 1 , wherein the compound is selected from the group consisting of:

and a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein IRAK is at least one selected form the group consisting of IRAK-1 and IRAK-4.